ORIGINAL RESEARCH

Patient-reported outcome after treatment for definite Lyme neuroborreliosis

Randi Eikeland1,2 | Unn Ljøstad3,4 | Geir Helgeland5 | Geir Sand6 | Heidi Øyen Flemmen7 | Margrete Halvorsen Bø8 | Ludmila Nordaa9 | Jone Furulund Owe10 | Åse Mygland3,4,11 | Åslaug Rudjord Lorentzen2,3

1Department of Pediatrics, Sørlandet Hospital Trust, Arendal, Norway
2The Norwegian National Advisory Unit on Tick-borne Diseases, Arendal, Norway
3Department of Neurology, Sørlandet Hospital Trust, Kristiansand, Norway
4Department of Clinical Medicine, University of Bergen, Bergen, Norway
5Department of Neurology, Møre and Romsdal Hospital Trust, Molde, Norway
6Department of Infectious Diseases, Stavanger University Hospital, Stavanger, Norway
7Department of Neurology, Telemark Hospital Trust, Skien, Norway
8Department of Neurology, Oslo University Hospital, Oslo, Norway
9Department of Neurology, Helse Fonna Trust, Haugesund, Norway
10Department of Neurology, Haukeland University Hospital, Bergen, Norway
11Department of Rehabilitation, Sørlandet Hospital Trust, Kristiansand, Norway

Correspondence
Randi Eikeland, The Norwegian National Advisory Unit on Tick-borne Diseases, Sørlandet Hospital Trust, Postbox 783, N-4809 Arendal, Norway.
Email: randi.eikeland@sshf.no

Present address
Geir Helgeland, Eide legesenter as, Eide, Norway
Ludmila Nordaa, N.K.S. Jæren distriktssykehus senter AS, Bryne, Norway

Funding information
This work was funded by the South-Eastern Norway Regional Health Authority, Grant number 2013089.

Abstract

Objective: To chart patient-reported outcome measures (PROMs) in Norwegian patients treated for definite neuroborreliosis (NB).

Material and Methods: Adult patients treated for definite NB 1–10 years earlier supplied demographics, symptoms and treatment during NB, and answered validated questionnaires: Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), health-related quality of life questionnaire (RAND-36), and Patient Health Questionnaire (PHQ-15).

Results: A higher proportion of NB-treated persons reported severe fatigue, defined as FSS score ≥ 5, than in Norwegian normative data, but when removing persons with confounding fatigue associated comorbidities (n = 69) from the analyses, there was no difference between groups. Physical health-related quality of life (RAND-36 PCS), mean FSS score, proportions of persons reporting moderate or severe somatic symptom burden (PHQ-15 score ≥ 10), anxiety (HADS-A ≥ 8), or depression (HADS-D ≥ 8) did not differ between NB-treated persons and reference scores. Mental health-related quality of life (RAND-36 MCS) was poorer than in normative data (47.1 vs. 53.3), but associated with anxiety, depression and current moderate or severe somatic symptom burden, and not with NB characteristics.

The peer review history for this article is available at https://publons.com/publon/10.1002/brb3.1595

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2020 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.
1 | INTRODUCTION

Most patients recover well after treated neuroborreliosis (NB; Obel et al., 2018), but some report residual symptoms as pain, paresthesias, fatigue, and cognitive deficits (Eikeland, Ljestad, Mygland, Herlofson, & Lohaugen, 2012; Eikeland, Mygland, Herlofson, & Ljestad, 2011; Knudtzen, Andersen, Jensen, & Skarphedinsson, 2017; Ljøstad & Mygland, 2010). Almost all aspects of the phenomenon postborreliosis symptoms are debated, including its existence, prevalence, cause, spectrum, and impact (Halperin, 2017). In a meta-analysis of 34 studies, Dersch, Sommer, Rauer, and Meerpohl (2016) found that about 28% of patients treated for NB had residual symptoms, most often pain. The prevalence was highest in studies using diffuse NB case definition. The authors debate whether the results are biased and if reports of debilitating fatigue and cognitive impairment after NB could “be an artifact of unspecific case definitions in single studies”. It is also of note that several of the included studies did not use validated and standardized outcome measures. For future studies, it was recommended to apply strict case definitions and to put more emphasis on impact of residual symptoms.

In the current study, we aimed to chart long-term prognosis of NB by collecting patient-reported outcome measures (PROMs) using validated questionnaires in persons treated for definite NB according to current diagnostic guidelines (Mygland et al., 2010).

2 | MATERIAL AND METHODS

2.1 | Study design

Cross-sectional study.

2.2 | Patient recruitment

All departments of Neurology in Norway were invited to identify and recruit patients by reviewing medical records. Inclusion criteria were adult patients (≥18 years) treated for definite NB according to the EFNS diagnostic guidelines (neurological symptoms suggestive of NB without other obvious reasons, pleocytosis in CSF and intrathecal Borrelia burgdorferi antibody production; Mygland et al., 2010) between 2006 and 2014. Twelve out of 18 invited hospitals agreed to participate. A contact person at each department reviewed the medical records for eligible patients (n = 598) and invited them per letter to fill in the PROM questionnaires, preferred web-based, but optional paper-based during 2015 to 2016.

2.3 | Variables and questionnaires

Year of NB diagnosis and CSF cell count were obtained from medical records.

2.4 | Patient-reported information about education level

Questions about education were obtained by reuse of formulations from the Nord-Trendelag Health Study 3 (HUNT3), which is a Norwegian community-based survey (Krokstad et al., 2013).

2.5 | Patient-reported information about NB

2.5.1 | Symptoms

The patients were asked if they had experienced any of the following symptoms during their NB: Headache, fatigue, malaise, general pain, radiating pain from neck or back, facial palsy, paresis, numbness, memory or concentration problems, dizziness or unsteadiness, diplopia, or other. A sum score of symptom burden during NB was provided by giving each “yes” one point (max score 12).

2.5.2 | Treatment

The patients were asked if they were treated with orally or intravenously administered antibiotics or both, and for how many weeks

Conclusions: Results on validated PROM questionnaires measuring fatigue, anxiety, depression, self-reported somatic symptom burden, and physical health-related quality did not differ between persons treated for definite NB 1–10 years earlier and reference scores. NB-treated persons tended to report a slightly poorer mental health-related quality of life than found in normative data, but when adjusting for confounders the causative connection is questionable. Overall, the long-term prognosis of definite NB seems to be good.

KEYWORDS

fatigue, neuroborreliosis, patient-reported outcome measures
(by ticking off 1–6). For both questions, “I do not remember” was an optional answer.

2.6 | Patient-reported information about comorbidity

The patients were asked if they had ongoing or previous any of the following comorbidities: diabetes mellitus, metabolic disease, rheumatoid arthritis, fibromyalgia, systemic disease (sarcoidosis, systemic lupus erythematosus, or Sjögren’s syndrome), other musculoskeletal disease, multiple sclerosis, Parkinson’s disease, dementia, epilepsy, stroke, polyneuropathy, other neurological diseases, cancer, heart disease, asthma or chronic obstructive lung disease, allergy, chronic fatigue syndrome, depression or anxiety, other psychiatric disease, celiac disease, osteoporosis, kidney disease, other diseases not specified further. If they answered yes to one or more, the patients were classified as suffering from comorbidity. A sum score was provided by giving each “yes” one point (max score 24).

2.7 | Patient-reported outcome measures (PROMs)

2.7.1 | Fatigue

Fatigue Severity Scale (FSS) is a validated questionnaire (Krupp, LaRocca, Muir-Nash, & Steinberg, 1989) that measures level of agreement (1–7) with nine statements about fatigue. The final score represents the mean value of the nine items. Scores ≥ 5 are regarded as severe fatigue (Lerdal, Wahl, Rustæn, Hanestad, & Moum, 2005).

2.7.2 | Somatic symptom burden during the last 4 weeks

The Patient Health Questionnaire -15 (PHQ-15) is a validated questionnaire that charts prevalence and intensity of 15 somatic symptoms (stomach pain, back pain, pain in arms/legs/joints, menstrual cramps, or other problems with periods [women only], headache, chest pain, fainting spells, feeling of heartpounds or race, shortness of breath, pain or problems during sexual intercourse, constipation/loose bowels/diarrhea, nausea/gas/indigestion, feeling tired/having low energy, trouble sleeping) during the last 4 weeks (Kroenke, Spitzer, & Williams, 2002). The answers are graded “not bothered at all” (0 points), “bothered a little” (1 point), and “bothered a lot” (2 points). Sum score ranges from 0 to 28 for men and from 0 to 30 for women.

Scores 5–9 points, 10–14 points, and 15–30 points indicate mild, moderate, and severe somatic symptom burden, respectively (Zijlema et al., 2013). We translated the PHQ-15 questionnaire into Norwegian based on the Swedish version (Nordin, Palmquist, & Nordin, 2013). A missing value for a PHQ-15 item was replaced with the average value of the other items if the number of missing values did not exceed three items (n = 3; Kroenke et al., 2002).

2.7.3 | Anxiety and depression

Hospital Anxiety and Depression Scale (HADS) is a validated questionnaire measuring symptoms of anxiety and depression (Bjelland, Dahl, Haug, & Neckelmann, 2002). It includes seven anxiety items and seven depression items scored on a four-point Likert-like scale. Scores ≥ 8 on the subscales indicate a need of further assessment of possible anxiety and/or depression (Leiknes, Dalsbo, & Sigveland, 2016). A missing value in either the anxiety or depression items was replaced with the average value of the other items if the number of missing values did not exceed one item in each subscore (n = 2).

2.7.4 | Health-related quality of life

RAND-36 is a validated questionnaire that measures health-related quality of life (Ware, 2000). It consists of 36 questions comprising eight multi-item scales: mental health, vitality, bodily pain, general health, social function, physical function, and physical and emotional role. These domains are then combined into physical and mental component summary scales (PCS and MCS).

2.8 | Statistical analysis

Results are given as proportions, mean with standard deviations (SD), or median with range as appropriate. To calculate 95% confidence intervals of differences, we used online calculators http://vassarstats.net/prop2_ind.html (proportions) and https://www.socscistatistics.com/confidencinterval/Default4.aspx (means). Selected variables, considered to be of importance, were entered into a multivariate linear regression analysis with mental health-related quality of life (MCS) score as the dependent variable. p-Values < .05 were considered statistically significant. All statistical analyzes were performed using SPSS version 25 (SPSS Inc.).

2.9 | Ethics

The study was approved by the Norwegian Regional Committees for Medical and Health Research Ethics, and all patients gave a written informed consent (REK 2013/1325).

3 | RESULTS

Out of 598 invited NB patients, 307 gave a written informed consent to participate in the study, and 258 returned a satisfactorily
completed questionnaire (228 web-based, 30 paper), yielding a response rate of 43%. Of ethical reasons (lack of informed consent), we could not obtain data from the nonresponders to detect meaningful differences between those who responded and those who did not.

Patient characteristics at the time of filling the questionnaire are shown in Table 1. A total of 185 NB-treated patients (71%) reported to have at least one of the listed comorbidities, of which the most frequently reported were other musculoskeletal diseases (nonrheumatic, not fibromyalgia; 17%), allergy (14%), depression or anxiety (11%), and other not defined diseases (20%). Sixty-nine persons (27%) reported diseases often associated with fatigue as multiple sclerosis (3), systemic disease sarciodosis, systemic lupus erythematosus, or Sjögren’s syndrome (4), rheumatoid arthritis (9), fibromyalgia (10), chronic fatigue syndrome (4), Parkinson’s disease (1), thyroid dysfunctions (22), or cancer (28). Mean number of reported comorbidities was 1.4 (SD = 1.3).

Patient-reported information on clinical characteristics and treatment of the NB are shown in Table 2. Median CSF leukocyte count at the time of diagnosis was 171 10^6/L (range 5–3498 10^6/L), and 75% of the CSF samples had a leukocyte count between 62 and 296 10^6/L.

Patient-reported outcome measures, relevant reference scores, and estimated 95% CI of the differences between our findings and reference scores are shown in Table 3. A higher proportion of NB-treated persons reported severe fatigue, defined as FSS score ≥ 5, than in Norwegian normative data, but when removing persons with confounding fatigue associated comorbidities (n = 69) from the analyses, there was no difference between groups. Physical health-related quality of life (RAND-36 PCS), mean FSS score, proportions of persons reporting moderate or severe somatic symptom burden (PHQ-15 score ≥ 10), anxiety (HADS-A ≥ 8), or depression (HADS-D ≥ 8) did not differ between NB-treated persons and reference scores. Mental health-related quality of life (RAND-36 MCS) was poorer among NB-treated patients than in normative data. To further analyze this finding, we did a linear regression and found that poorer mental health-related quality of life was associated with HADS-A ≥ 8 (p < .001), HADS-D ≥ 8 (p < .001), and PHQ-15 ≥ 10 (p = .024), but not with sex, age, years since NB diagnosis, education level, treatment administration route, treatment duration, CSF cell count at diagnosis, burden of symptoms at diagnosis, memory and/or concentration problems at diagnosis, comorbidity, or FSS ≥ 5.

4 | DISCUSSION

The main results in the present study were that in our group of 258 Norwegian patients treated for definite NB one to ten years earlier the prevalence of severe fatigue, substantial symptomatic symptom burden, anxiety, and depression did not differ from relevant reference groups, and reported physical health-related quality of life was similar to normative data. Mental health-related quality of life tended to be slightly poorer among NB-treated patients, but was associated with anxiety, depression and presence of moderate or severe current subjective somatic symptom burden and not with any NB-related factors. Based on our findings, we therefore state that long-term prognosis of definite NB seems to be good.

Residual symptoms after treated NB is a much debated phenomenon (Halperin, 2017). Some have found residual symptoms in up to 50% (Eikeland et al., 2012; Eikeland et al., 2011; Knudtzen et al., 2017; Ljøstad & Mygland, 2010), while others have found that NB has no substantial effect on long-term survival, health, or educational and social functioning (Obel et al., 2018). Some of the disagreement may be explained by different study designs and poor case definitions (Dersch et al., 2016).

| TABLE 1 | Demographic features of the study population at the time of filling out the questionnaire |
|---------|--------------------------------------|
|          | Study patients n = 258 |
| Age, mean (SD) | 62.4 (12.7) |
| Females, n (%) | 129/258 (50) |
| Years since treatment for NB, mean (range) | 5.0 (1–10) |
| High educational level (university or college), n (%) | 111/257 (43) |

Abbreviation: SD, standard deviation.

| TABLE 2 | Patient-reported information about their Neuroborreliosis; clinical characteristics and treatment |
|---------|-------------------------------------------------|
|          | Study patients, n = 258 |
| Reported symptoms, n (%) | |
| Radiating pain | 120 (47) |
| General pain | 117 (45) |
| Fatigue | 116 (45) |
| Facial palsy | 109 (42) |
| Malaise | 108 (42) |
| Dizziness and/or unsteadiness | 91 (35) |
| Headache | 89 (35) |
| Numbness in arm and/or leg | 80 (31) |
| Memory and/or concentration problems | 75 (29) |
| Paresis in arm and/or leg | 48 (19) |
| Diplopia | 31 (12) |
| Other | 7 (3) |
| Total symptom burden (max score 12), median (range) | 4 (1–11) |
| Administration route of antibiotics, n (%) | |
| Exclusively oral | 76 (30) |
| IV or combined IV and oral | 181 (70) |
| Unknown | 1 |
| Treatment duration > 2 weeks, n (%) | 153/244 (63) |
Our study design does not permit any final conclusions or detection of causal connections, but our results give a substantial contribution to the debate. It is interesting that when we apply strict case definition and validated PROMs there seem to be very few residual symptoms 1–10 years after adequate treatment for NB. Some would argue that a recruitment rate of 43% might have caused a selection bias, and that the time from acute disease might have caused a recall bias, and that our findings therefore are unreliable. In our opinion, this is not a big error source, as one would expect both these potential biases to lead to over reporting of complaints rather than under reporting.

Further, comparison with normative data should be done with caution and have several caveats. Among other things, the populations may differ regarding gender, age, education level, and comorbidity, and also regarding cultural conditions, setting, and patient expectations. Nevertheless, the comparisons can express trends. Another study (Eikeland et al., 2011) using validated questionnaires have included matched control persons for comparison. They found poorer physical and mental health-related quality of life, and more fatigue among NB-treated persons than among controls, but case definitions in this study were less strict, as 16/50 (32%) were classified as possible NB.

**TABLE 3** Patient-reported outcome measures (PROMs) as compared to reference scores (normative data or other relevant reference groups)

| PROMs                        | Study patients | Reference scores                                                                 | 95% CI of the difference |
|------------------------------|----------------|----------------------------------------------------------------------------------|--------------------------|
| **Fatigue**                  |                |                                                                                  |                          |
| All responders n = 253       |                |                                                                                  |                          |
| FSS, mean (SD)               | 3.84 (1.88)    | Norwegian normative data (Lerdal et al., 2005) n = 1,893                       | -0.002 to 0.34           |
| FSS score ≥ 5                | 80 (32%)       | FSS, mean: 4.0, SD 1.3                                                          | 0.03 to 0.15             |
| Responders without fatigue associated comorbidities n = 184 |                |                                                                                  |                          |
| FSS, mean (SD)               | 3.63 (1.84)    |                                                                                  | 0.2 to 0.6               |
| FSS score ≥ 5                | 50 (27%)       |                                                                                  | -0.02 to 0.11            |
| **Anxiety and depression**   |                |                                                                                  |                          |
| Anxiety subscore             |                |                                                                                  |                          |
| HADS-A, mean (SD)            | 4.6 (3.7)      | Data from HUNT 2 and HUNT 3 (Leiknes et al., 2016)                             | 0.20 to 1.10             |
| HADS-A score ≥ 8             | 50/257 (19%)   | 4.0 (3.3) n = 39,277                                                            | -0.002 to 0.1            |
| Depression subscore          |                |                                                                                  |                          |
| HADS-D, mean (SD)            | 3 (3.0)        | 3.3 (2.9) n = 39,573                                                            | -0.25 to 0.46            |
| HADS-D score ≥ 8             | 26/255 (10%)   | 11.6% n = 7,014                                                                  | -0.03 to 0.05            |
| **Health-related quality of life** |              |                                                                                  |                          |
| RAND-36                      |                |                                                                                  |                          |
| PCS, mean (SD)               | 46.5 (9.7)     | Norwegian normative data (50–59 years; Garratt & Stavem, 2017) n = 947         | -0.16 to 2.76            |
| MCS, mean (SD)               | 47.1 (9.9)     | 53.3 (8.7)                                                                      | 4.95 to 7.45             |
| **Somatic symptom load**     |                |                                                                                  |                          |
| PHQ-15, mean (SD)            | All 6.2 (4.7)  | Swedish normative data (Nordin et al., 2013)                                    |                          |
| Women 6.8 (4.9)              | Women 7.2 (4.8) n = 1,898                                                   | -0.702 to 1.102          |
| Men 5.7 (4.3)                | Men 5.3 (4.4) n = 1,508                                                      | -0.199 to 1.399          |
| PHQ-15 score ≥ 10            | All 57/245 (23%)                                                     |                          |
| Women 35/117 (30%)           | Women 26.4% n = 1,898                                                      | -0.03 to 0.15            |
| Men 22/128 (17%)             | Men 14.8% n = 1,508                                                      | -0.005 to 0.15           |

Abbreviations: FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; MCS, Mental component summary scales; PCS, Physical component summary scales; PHQ-15, Patient Health Questionnaire-15; RAND-36, Short Form Health Survey. Bold indicate statistically significant values.
The mean age (62 years) in our cohort was rather high, and a substantial proportion reported to have comorbidity (71%), thus one would expect a certain amount of reported symptoms due to other reasons than previous NB. Unfortunately, we did not ask whether the patients attributed their current complaints to the previous NB or to other comorbidities. Instead, we adjusted for this confounder by removing persons with fatigue associated comorbidity when comparing fatigue scores. By doing this, there was no difference between NB-treated patients and normative data, and mean FSS score changed from similar to lower in the NB-treated group. We therefore think that even if the question about causality between the PROMs and NB is impossible to answer with our study design, it is proper to state that NB-treated persons do not suffer from more fatigue than found in normative data.

Previous prospective studies have found that residual symptoms after treated NB is associated with factors as pretreatment symptom duration > 6 weeks, pretreatment burden of symptoms and findings, pretreatment CSF leukocyte count, and female gender (Eikeland, Mygland, Herlofson, & Ljøstad, 2013; Knudtzen et al., 2017; Ljøstad & Mygland, 2010). We did not find any association between the only PROM that differed between NB-treated persons and reference data, namely mental health-related quality of life, and pretreatment CSF leukocyte count and symptom burden. Instead, poor mental health-related quality of life was associated with anxiety, depression, and moderate or severe symptom burden last 4 weeks, and we therefore assume that the impairment was caused by other factors than NB.

5 | CONCLUSION

Results on validated PROM questionnaires measuring fatigue, anxiety, depression, self-reported somatic symptom burden, and physical health-related quality did not differ between persons treated for definite NB 1–10 years earlier and reference scores. NB-treated persons tended to report a slightly poorer mental health-related quality of life than found in normative data, but when adjusting for confounders the causative connection is questionable. Although our study has several shortcomings, we conclude that the long-term prognosis of definite NB seems to be good.

ACKNOWLEDGMENTS

We are grateful to the patients that participated in the study. Tone A. Melum at Department of Neurology, University Hospital of North Norway, Tromsø, Ida Bakke at Department of Neurology, Nordland Hospital Trust, Bodø, Stephan Schüler at Department of Neurology, Nord-Trøndelag Trust, Namssos, Anna Roos and Lise Rystad Øien at Department of Neurology, St. Olavs University Hospital, Trondheim, Kaja Nyquist at Department of Neurology, Innlandet Hospital, Lillehammer Trust, Marion W. Jim at Department of Neurology, Vestre Viken Trust, Drammen, Kristine J.N. Forselv at Department of Neurology, Sørlandet Hospital Trust, Kristiansand, Rigmor E. Salvesen at Department of Neurology, Stavanger University Hospital, Stavanger and Audun Dahlberg, Department of Neurology, Møre and Romsdal Trust, Molde are all thanked for looking into clinical files searching for neuroborreliosis patients.

CONFLICT OF INTEREST

The authors have no conflict of interest.

AUTHOR CONTRIBUTIONS

ÅL was responsible for conception and design of the study, for data acquisition, analysis and interpretation. RE, UL, and ÅM were responsible for conception and design of the study, data analysis and interpretation. GH, GS, HØF, MHB, LN, JFO included patients in the studies, and all authors revised and approved the final version of the manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Randi Eikeland https://orcid.org/0000-0003-0104-9626
Åslaug Rudjord Lorentzen https://orcid.org/0000-0002-6918-4157

REFERENCES

Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *Journal of Psychosomatic Research, 52*(2), 69–77. https://doi.org/10.1016/s0022-3991(01)00296-3

Dersch, R., Sommer, H., Rauer, S., & Meerpohl, J. J. (2016). Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: A systematic review. *Journal of Neurology, 263*(1), 17–24. https://doi.org/10.1007/s00415-015-7923-0

Eikeland, R., Ljøstad, U., Mygland, A., Herlofson, K., & Lohaugen, G. C. (2012). European neuroborreliosis: Neuropsychological findings 30 months post-treatment. *European Journal of Neurology, 19*(3), 480–487. https://doi.org/10.1111/j.1468-1311.2011.03563.x

Eikeland, R., Mygland, A., Herlofson, K., & Ljøstad, U. (2011). European neuroborreliosis: Quality of life 30 months after treatment. *Acta Neurologica Scandinavica, 124*(5), 349–354. https://doi.org/10.1111/j.1600-0404.2010.01482.x

Eikeland, R., Mygland, Å., Herlofson, K., & Ljøstad, U. (2013). Risk factors for a non-favorable outcome after treated European neuroborreliosis. *Acta Neurologica Scandinavica, 127*(3), 154–160. https://doi.org/10.1111/j.1600-0404.2012.01690.x

Garrett, A. M., & Stavem, K. (2017). Measurement properties and normative data for the Norwegian SF-36: Results from a general population survey. *Health and Quality of Life Outcomes, 15*(1), 51–51. https://doi.org/10.1186/s12955-017-0625-9

Halperin, J. J. (2017). Neuroborreliosis. *Journal of Neurology, 264*(6), 1292–1297. https://doi.org/10.1007/s00415-016-8346-2

Knudtzen, F. C., Andersen, N. S., Jensen, T. G., & Skarpheðinsson, S. (2017). Characteristics and clinical outcome of Lyme neuroborreliosis in a high endemic area, 1995–2014: A retrospective cohort study in Denmark. *Clinical Infectious Diseases, 65*(9), 1489–1495. https://doi.org/10.1093/cid/cix568

Kroenke, K., Spitzer, R. L., & Williams, J. B. (2002). The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. *Psychosomatic Medicine, 64*(2), 258–266.
Krokstad, S., Langhammer, A., Hveem, K., Holmen, T., Midtbjøll, K., Stene, T., ... Holmen, J. (2013). Cohort profile: The HUNT study, Norway. *International Journal of Epidemiology*, 42(4), 968–977. https://doi.org/10.1093/ije/dys095

Krupp, L. B., LaRocca, N. G., Muir-Nash, J., & Steinberg, A. D. (1989). The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Archives of Neurology*, 46(10), 1121–1123. https://doi.org/10.1001/archneur.1989.00520460115022

Leiknes, K. A., Dalsbo, T. K., & Siqveland, J. (2016). Psychometric assessment of the Norwegian version of the Hospital Anxiety and Depression Scale (HADS). Retrieved from https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2016/rapport_2016_hads_maleegenskaperv4-u-vedlegg1.pdf

Lerdal, A., Wahl, A., Rustøen, T., Hanestad, B. R., & Moum, T. (2005). Fatigue in the general population: A translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. *Scandinavian Journal of Public Health*, 33(2), 123–130. https://doi.org/10.1080/14034940410028406

Ljøstad, U., & Mygland, A. (2010). Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. *European Journal of Neurology*, 17(1), 118–123. https://doi.org/10.1111/j.1468-1331.2009.02756.x

Mygland, A., Ljøstad, U., Fingerle, V., Rupprecht, T., Schmutzhard, E., & Steiner, I. (2010). EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. *European Journal of Neurology*, 17(1), 8–16, e11–14. https://doi.org/10.1111/j.1468-1331.2009.02862.x

Nordin, S., Palmquist, E., & Nordin, M. (2013). Psychometric evaluation and normative data for a Swedish version of the Patient Health Questionnaire 15-Item Somatic Symptom Severity Scale. *Scandinavian Journal of Psychology*, 54(2), 112–117. https://doi.org/10.1111/j.1035-6999.2009.012029

Obel, N., Dessau, R. B., Krogfelt, K. A., Bodilsen, J., Andersen, N. S., Møller, J. K., ... Lebech, A.-M. (2018). Long term survival, health, social functioning, and education in patients with European Lyme neuroborreliosis: Nationwide population based cohort study. *BMJ*, 361, k1998. https://doi.org/10.1136/bmj.k1998

Thortveit, E. T., Lorentzen, Å. R., Ljøstad, U., & Mygland, Å. (2019). Somatic symptoms and fatigue in a Norwegian population with high exposure to ticks. *Ticks and Tick-borne Diseases*, 10(1), 156–161. https://doi.org/10.1016/j.ttbdis.2018.09.012

Ware, J. E., Jr. (2000). SF-36 health survey update. *Spine*, 25(24), 3130–3139.

Zijlema, W. L., Stolk, R. P., Lowe, B., Rief, W., White, P. D., & Rosmalen, J. G. (2013). How to assess common somatic symptoms in large-scale studies: A systematic review of questionnaires. *Journal of Psychosomatic Research*, 74(6), 459–468. https://doi.org/10.1016/j.jpsychores.2013.03.093

How to cite this article: Eikeland R, Ljøstad U, Helgeland G, et al. Patient-reported outcome after treatment for definite Lyme neuroborreliosis. *Brain Behav*. 2020;10:e01595. https://doi.org/10.1002/brb3.1595